David Piacquad - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Senior Vice President - Business Development

Mr. David A. Piacquad is the Senior Vice President Business Development of Amgen Inc. Mr. Piacquad joined the Company in June 2010 and, until January 2014, served as Vice President, Strategy and Corporationrationrate Development. From January 2014 to March 2014, Mr. Piacquad served as Vice President, Business Development. Prior to joining the Company, from December 2009 to June 2010, Mr. Piacquad was Principal of David A. Piacquad Consulting LLC. From March 2006 to December 2009, Mr. Piacquad served as Senior Vice President, Business Development and Licensing for ScheringPlough Corporationrationration. Prior to ScheringPlough, Mr. Piacquad served in a series of leadership roles in finance and business development at JJ, with his last position being Vice President, Ventures and Business Development.
Age: 59  President Since 2014      
805-447-1000  http://www.amgen.com

David Piacquad Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Daniel SkovronskyEli Lilly and Company
2018
Annette TumoloBio Rad Laboratories
2017
Gary PhillipsMallinckrodt Public Limited Com
2016
Jaime ContrerasAbbott Laboratories
2013
Eric FainAbbott Laboratories
2017
Sanat ChattopadhyayMerck Co
2016
Alfonso ZuluetaEli Lilly and Company
2017
Georges VosAbbott Laboratories
2013
Enrique ConternoEli Lilly and Company
2017
Terrance CarlsonMallinckrodt Public Limited Com
2015
Terrance CoughlinEndo International plc
2016
John HertiaBio Rad Laboratories
2014
Michael HolstonMerck Co
2015
Matthew MalettaEndo International plc
2015
Michael PariniVertex Pharmaceuticals Incorpor
2017
Ann JudgeBristol Myers Squibb Company
2016
Joseph ManningAbbott Laboratories
2017
Brian LortieEndo International plc
N/A
Hugh ONeillMallinckrodt Public Limited Com
2017
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
JeanYves PaveeAbbott Laboratories
2015

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.